Agios Pharmaceuticals Inc. (AGIO)
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
AGIO seeks FDA accelerated approval for mitapivat in sickle cell disease after mixed phase III data and a planned confirmatory study.
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum
Agios shares jump 13% as Q1 revenues surge 138% on Aqvesme launch and Pyrukynd growth, while pipeline advances and SCD filing plans take shape.
Agios Pharmaceuticals, Inc. (AGIO) Q1 2026 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (AGIO) Q1 2026 Earnings Call Transcript
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.69 per share versus the Zacks Consensus Estimate of a loss of $1.81. This compares to a loss of $1.55 per share a year ago.
Earnings Preview: Agios Pharmaceuticals (AGIO) Q1 Earnings Expected to Decline
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
Agios Pharmaceuticals jumps 14% as it moves toward accelerated FDA approval for mitapivat in sickle cell disease after key regulatory feedback.
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why
AGIO sinks 23% as mixed phase III data for mitapivat in SCD and an FDA review delay for thalassemia dent investors' confidence in its key growth drug.
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss
AGIO beats fourth-quarter estimates for both the top and bottom lines as Pyrukynd sales jump 49% year over year.
Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $1.97. This compares to a loss of $1.74 per share a year ago.
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
